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Abstract
Background: An increasing amount of evidence has demonstrated an association between an increase in the level
of tumor necrosis factor superfamily 13 (TNFSF13) and immunoglobulin A nephropathy (IgAN) progression. We aimed
to evaluate if the level of pre-transplant serum TNFSF13 is predictive of IgAN recurrence after kidney transplantation.
Methods: This analysis was based on the clinical and laboratory data of 69 patients with IgAN who underwent first
kidney transplantation with no evidence of mesangial IgA deposits in zero-time transplantation biopsy. We measured
pre-transplant serum TNFSF13, total IgA, and galactose-deficient IgA1 levels.
Results: The recurrence rate of IgAN over a median follow-up duration of 5.1 years was 15.9% (11/69 patients), with a
mean time to the first recurrence of 1.7 years. The high pre-transplant TNFSF13 level was associated with
IgAN recurrence after kidney transplantation among patients who received a graft from a living related donor.
Conclusions: This study highlights association of TNFSF13 levels in recurrent IgAN patients who undergo
living related donor transplantation. Further research is needed to clarify mechanisms by which TNFSF13
affects the recurrence of IgA nephropathy.
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Background
Immunoglobulin A nephropathy (IgAN) is the most com-
mon type of primary glomerulonephritis [1, 2], and a sig-
nificant number of patients progress to end-stage renal
disease (ESRD) requiring dialysis or kidney transplantation
[3]. In cases of transplant recipients, recurrence of primary
glomerulonephritis commonly affects graft and patient
outcomes [2]. The recurrence rate of IgAN after kidney
transplantation has been estimated to be 9 to 61%, with
this wide variability likely to reflect differences in
follow-up duration and biopsy policies across institutions
[4, 5]. While the impact of the recurrence of IgA deposits
on graft function has been debated, recurrent IgAN has
been associated with unfavorable outcomes in long-term
follow-up studies [2, 6–8]. Unfortunately, however,
there is no biomarker that can predict IgAN recurrence in
these patients.
Tumor necrosis factor superfamily 13 (TNFSF13), also
known as a proliferation inducing ligand (APRIL), is se-
creted from antigen-presenting cells and is engaged in
adaptive and innate immune responses by binding to re-
ceptors on B and T cells [9, 10]. An in vivo analysis using
TNFSF13 gene knockout mice showed impaired IgA anti-
body responses to mucosal immunization [11]. Con-
versely, TNFSF13 transgenic mice showed enhanced
T-cell independent humoral responses [12]. The TNFSF13
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locus has recently been identified as a susceptibility gene
in a Han Chinese genome-wide association study of IgAN
patients [13]. Furthermore, high serum TNFSF13 levels in
IgAN patients could predict the progression of renal dis-
ease based on B cell stimulation [14]. The high recurrence
rates after kidney transplantation in IgAN patients sug-
gests an impaired host IgA immune system. Therefore,
TNFSF13, which is known to be involved in B cell and im-
munoglobulin A immune system function, could affect re-
current IgAN. The objective of this study was to find an
association between pre-transplant serum TNFSF13 levels
and recurrent IgAN.
Methods
Patients and data collection
Between January 2011 and October 2015, 80 patients
with biopsy-proven IgAN underwent kidney transplant-
ation at our institution. Among these patients, we en-
rolled 69 who underwent first kidney transplantation
and did not show mesangial IgA deposits on biopsy at
the time of kidney transplantation and have allograft bi-
opsy data within one year after transplantation. The fol-
lowing information was extracted from medical records
for analysis: age, sex, renal replacement therapy, the
donor age and sex, number of human leukocyte antigen
(HLA) mismatches, ABO mismatch, donor type,
desensitization treatment, induction treatments adminis-
tered, withdrawal of steroid treatment and acute rejec-
tion events and trough level of tacrolimus within one
year after kidney transplantation. Highly sensitized pa-
tients defined as having panel reactive antibody higher
than 50% [15]. Allograft failure was defined by the need
to re-initiate dialysis or when the estimated glomerular
filtration rates (eGFR) fell below 15 mL/min/1.73 m2.
Clinicopathologic recurrence of IgAN after kidney trans-
plantation was defined as a clinically evident disease
with deteriorating renal function and identification of
mesangial IgA deposits on immunofluorescence staining
with mesangial hypercellularity in allograft biopsy tissue
[16]. Renal function decline was defined as eGFR-time
slope, differences in eGFR between the peak value in the
post-transplant period within 2 months after kidney
transplantation and the nadir value at the time of last
follow up time divided by follow up duration.
Laboratory tests
Of the 69 IgAN patients initially enrolled in the study,
serum samples at the time of kidney transplantation to
quantify pre-transplant TNFSF13 levels were obtained from
62 patients. We also recruited the serum samples from
non-ESRD IgAN patients who had eGFR > 30mL/min/1.73
m2. The samples were frozen at − 80 °C until analysis. Serum
levels TNFSF13 were quantified using an enzyme-linked im-
munosorbent assay (ELISA) kit (eBioscience, San Diego,
CA, USA), based on previously published methods [14].
Serum Gd-IgA1 levels were quantified using a lectin ELISA
with Helix promatia agglutinin. Serum Gd-IgA1 levels were
expressed in U/mL, where 1U of Gd-IgA1 was defined as
10.0 μg of standard, and 1U/mL was expressed as 1U/ng
IgA after normalization to total IgA levels. We purified
Gd-IgA1 from an IgAN patient’s plasma using immobilized
Jacalin (Thermo Scientific, Rockford, IL, USA) for the
Gd-IgA1 method, as previously reported [14].
Statistical analysis
Comparisons were performed between patients with and
without recurrent IgAN after kidney transplantation. The
data are presented as the mean ± standard deviation (S.D)
for continuous variables and as proportions for categorical
variables. Differences between recurrent and non-recurrent
group were evaluated using the t-test for normally distrib-
uted continuous variables and Mann-Whitney U test for
non-normally distributed continuous variables. The
chi-squared or Fisher’s exact test was used for categorical
variables. A Cox regression model was used to calculate
the unadjusted and adjusted hazard ratios (HRs) and the
95% confidence intervals (CIs) for the factors that were as-
sociated with IgAN recurrence after kidney transplant-
ation. The interaction terms between TNFSF13 and
adjusted variables were confirmed by Cox analysis. A
p-value < 0.05 was considered statistically significant. All
statistical analyses were performed using IBM®SPSS® soft-
ware, version 21.0 (IBM Corporation, Armonk, NY, USA).
Results
Baseline characteristics and clinical outcomes
This study included 40 men (58.0%) and 29 women who
underwent first kidney transplantation for ESRD due to
biopsy-proven IgAN. At the time of transplantation,
their mean age was 43.7 years (Table 1). Over a median
follow up of 1865 days (mean, 1835 days), there were no
mortalities, and one case of allograft failure caused by
the patient discontinuing the immunosuppressive ther-
apy was observed. Recurrent IgAN were identified in 11
patients (15.9%). Among these cases, 3 received de-
ceased donor grafts, 1 received an unrelated living donor
graft and the other 7 received related living donor grafts.
There was no difference between the recurrent and
non-recurrent groups in the proportions of patients
treated with tacrolimus, cyclosporine or mycophenolate
mofetil. Also, the proportion of patients who received a
desensitization treatment and highly sensitized patients
who had panel reactive activity over 50% were not differ-
ent between the groups. The rate of acute rejection was
marginally higher among patients with than without
IgAN recurrence (p = 0.056). Pre-transplant serum
TNFSF13 levels in the study population were signifi-
cantly higher than in the 382 patients with non-ESRD
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IgAN (mean 1.75 ± 11.94 ng/mL) (Fig. 1). However, the
levels were not different between the recurrent (mean
17.75 ± 14.14 ng/mL) and non-recurrent (mean 15.66 ±
12.79 ng/mL) groups (Fig. 1). Specific HLA types (A2,
B35, and DR4) and pre-transplant serum levels of
TNFSF13 and galactose deficient IgA1 (Gd-IgA1) were
equivalents between groups. The eGFR-time slope was
steeper in the recurrent than in the non-recurrent group,
although this difference was not statistically significant.
Correlation between TNFSF13 levels and IgAN recurrence
after kidney transplantation among patients who
received living related donor grafts
We did identify a specific association between pre-trans-
plant serum TNFSF13 levels with IgAN recurrence
among patients who received living related donor grafts in
an interaction analysis (Table 2), though not significant all
transplant patients (adjusted HR, 1.111; p = 0.620). There
was a significant interaction between pre-transplant serum
TNFSF13 levels with living related transplantation for re-
current IgAN (p = 0.018). Pre-transplant TNFSF13 levels
were associated with an increased risk of IgAN recurrence
among patients who received a graft from a living related
donor after adjusting the recipient’s age and follow up
duration (Table 3, HR, 1.685; p = 0.025). Patients who re-
ceived a graft from a living related donor were dichoto-
mized based on the median pre-transplant serum
TNFSF13 level (9.97 ng/mL). Recurrence-free survival was
significantly lower among patients with a pre-transplant
serum TNFSF13 level greater than median values (Fig. 2).
Discussion
Several factors, including genetic and environmental fac-
tors, contribute to the pathogenesis of IgAN. Among the
several factors involved in the pathogenesis of IgAN, ab-
normal mucosal immunity is an important factor for
Table 1 Baseline characteristics of the study subjects
All Recurrence Non-recurrence p-value
Patients, n 69 11 58 –
Age, years 43.7 ± 13.4 43.4 ± 13.5 43.8 ± 13.5 0.923
Sex (male/female) 40/29 10/1 28/30 0.019
Dialysis/Preemptive kidney transplantation 53/16 9/2 44/14 1.000
Living related donor 36 (52.2) 7 (63.6) 29 (50.0) 0.406
Panel reactive activity > 50% 10 (14.5) 0 (0) 10 (17.2) 0.345
Desensitization treatment 13 (18.8) 1 (9.1) 12 (20.7) 0.676
Number of HLA mismatches 2.88 ± 1.84 2.45 ± 1.97 2.97 ± 1.82 0.354
ABO incompatible transplantation 10 (14.5) 1 (9.1) 9 (15.5) 1.000
Induction treatment (ATG/anti-IL-2) 0/68 0/10 0/58 0.159
Mean follow up duration after transplantation (days) 1835 ± 440 1782 ± 542 1845 ± 423 0.663







Acute rejection 32 (46.4) 8 (72.7) 24 (41.4) 0.056
Mean time of recurrence of IgA on allograft (days, IQR) – 614 ± 443
(390–726)
– –
Serum creatinine (at time of recurrence, mg/dL) 2.96 ± 1.52
eGFR-time slope (delta eGFR/year) −3.64 ± 4.88 −4.50 ± 3.99 −3.47 ± 5.04 0.302
HLA-A2 30 (43.5) 6 (54.5) 24 (41.4) 0.514
HLA-B35 12 (17.4) 2 (18.2) 10 (17.2) 1.000
HLA-DR4 40 (58.0) 9 (81.8) 31 (53.4) 0.104
Tacrolimus 66 (95.7) 10 (90.9) 56 (96.6) 0.411
Cyclosporine 7 (10.1) 2 (18.2) 5 (8.6) 0.309
Mycophenolate mofetil 53 (76.8) 7 (63.6) 46 (79.3) 0.265
Trough level of tacrolimus within one year from transplantation 8.30 ± 1.70 8.92 ± 1.38 8.19 ± 1.74 0.218
TNFSF13 (ng/mL) 16.03 ± 12.95 17.75 ± 14.14 15.66 ± 12.79 0.525
Gd-IgA1 (units/ng IgA) 5.77 ± 6.79 3.28 ± 1.43 6.35 ± 7.40 0.208
HLA human leucocyte antigen, ATG anti-thymocyte globulin, IL-2 interleukin-2, IQR interquartile range, eGFR estimated glomerular filtration rate, TNFSF13 Tumor
necrosis factor superfamily 13, Gd-IgA1 Galactose deficient-IgA1
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triggering IgAN. As previously noted, TNFSF13 is
known to be involved in abnormal mucosal immunity
via T-cell independent production of IgA- producing B
cells and IgA1 to IgA2 class switching [9, 17–20].
TNFSF13 levels can affect the etiology of recurrent
IgAN, based on findings of various studies about the ef-
fect of TNFSF13 on the IgA mucosal immune system
[11, 14]. It is well known that a longer follow-up period
after transplantation and younger age of a recipient at
transplantation increase the risk of IgAN recurrence [2].
A previous study reported a high recurrence rate of
IgAN after kidney transplantation among recipients with
zero-HLA mismatches [21]. In our study, we identified
that a higher pre-transplant serum level of TNFSF13
was associated with IgAN recurrence on multivariate
analysis among patients who received a graft from a liv-
ing related donor after adjusting for the recipient’s age at
transplantation, the length of follow up duration.
We could not elucidate why there was an association
between the levels of TNFSF13 on the recurrent IgAN
only in living related donor graft but not in entire sub-
jects. Although the mechanism of increased recurrent
IgAN in living related grafts is unclear, several explana-
tions could be possible. First, TNFSF13 shown to be in-
creased the overall IgA secretion, although not specific
to Gd-IgA1 [14]. However, unfortunately, we could not
confirm that TNFSF13 would affect recurrent IgAN via
increasing the relative amount of Gd-IgA1 because there
were no differences in the level of Gd-IgA1 between the
groups. Second, the pathogenesis of IgAN requires
Fig. 1 Comparison of serum TNFSF13 levels in patients with recurrent, non-recurrent immunoglobulin A nephropathy and patients with
immunoglobulin A nephropathy not on dialysis. *p = 0.000, n.s: non-significant
Table 2 An interaction analysis between pre-transplant serum TNFSF13 levels and adjusted variables for recurrent IgA nephropathy
Variables Adjusted HR 95% CI p-value for interaction
Recipient age≥ 50 years 0.981 0.915–1.052 0.597
Donor age ≥ 50 years 1.017 0.976–1.060 0.427
HLA full matches 1.054 0.960–1.158 0.266
ABO mismatch 0.985 0.830–1.170 0.864
Follow up duration ≥2000 days 1.030 0.993–1.069 0.115
Gd-IgA1 (units/ng IgA) 0.995 0.985–1.006 0.370
Living related donor 1.046 1.008–1.085 0.018
HR: hazard ratio, 95% CI: confidence interval. The hazard ratio was expressed as 1 units of Gd-IgA1/ng IgA increase
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several hits, and we carefully assume there was the role
of TNFSF13 in the production of anti-glycan antibody. It
is essential for the generation of anti-glycan IgG due to a
defect of allorecognition to Gd-IgA1 in the pathogenesis
of IgAN [22]. A recent study has shown that TNFSF13
also involved in adaptive immunity through influencing
on memory T cells [23]. We could not measure anti-glycan
antibodies in the present study; however, we carefully sug-
gest that TNFSF13 would affect recurrent IgAN by en-
gaging in alloantibody response. Third, the similar genetic
background in the living related grafts with recipients
would have affected the recurrent IgAN [24]. It can be in-
ferred that the mesangial immune complex deposition of
living related grafts is more likely to occur [25, 26].
TNFSF13 may have upregulated the production of sys-
temic IgA or pathognomonic IgA1-immune complex, and
these factors may be profound in living related donor grafts
having the genetic susceptibility. This issue would be re-
solved by the further experimental investigation.
Although IgAN was traditionally considered as a benign
disease, more recent evidence has demonstrated that re-
currence of IgAN in renal allografts is associated with un-
favorable outcomes in graft function [2, 8, 27, 28]. In this
study, we observed only one event of graft failure due to
the self-discontinuing steroid. Therefore, we did not find
an association between serum TNFSF13 levels and graft
outcome. Additionally, we did not identify an HLA-specific
effect, as reported in previous studies, including a negative
effect for HLA-B35 and DR4 and a protective effect for
HLA-A2 [6, 29]. As the majority of the patients in our
study group received anti-interleukin 2 for induction ther-
apy, we were unable to demonstrate the protective role of
antithymocyte globulin induction therapy on IgAN recur-
rence, as reported in a previous study [30].
According to Australia and New Zealand Dialysis and
Transplant (ANZDATA) registry, which has accumu-
lated data over 30 years, showed that recurrence of IgAN
was 5.1, 15% at 5, 15 years after kidney transplantation
[2]. The rate of IgAN recurrence in our study was 15.9%
over a median follow up duration of 5.1 years, a rate
which was higher than the rate based on the ANZDATA
registry data but lower than recurrence rate of 29–61%
reported in other studies [4, 29]. Differences in reported
rates of IgAN recurrence might result from differences
in biopsy policy between institutions and differences in
the length of follow up. Further prospective studies with
Table 3 Hazard ratios for recurrent immunoglobulin A nephropathy in patients who underwent kidney transplantation with living-
related donor grafts (n = 36)
Variables Unadjusted
HR
95% CI p-value Adjusted
HR
95% CI p-value
Recipient age 1.003 0.952–1.057 0.902 1.006 0.947–1.068 0.846
Donor age 0.988 0.924–1.056 0.718
HLA full matches 2.037 0.394–10.541 0.396
ABO mismatch 0.554 0.066–4.625 0.586
Follow up duration 0.999 0.997–1.001 0.332 0.999 0.997–1.001 0.198
Gd-IgA1 (units/ng IgA) 0.881 0.644–1.205 0.427
TNFSF 13 (10 ng/mL) 1.585 1.030–2.439 0.036 1.685 1.068–2.658 0.025
HR: hazard ratio, 95% CI: confidence interval. The hazard ratio was expressed as 1 units of Gd-IgA1/ng IgA increase, 10 ng/mL TNFSF13 increase
Fig. 2 Kaplan-Meier survival curves of recurrence after kidney transplantation in immunoglobulin A nephropathy patients who received living
related donor grafts according to the median levels of pre-transplant serum TNFSF13
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sufficient follow-up duration are needed to clarify the as-
sociation between pre-transplant serum TNFSF13 levels
and the recurrence rate and graft functionality in IgAN
patients.
The present study has several limitations. The number
of total subjects and events in the present study was too
small to obtain the predictive value of TNFSF13 for re-
current IgAN. Relatively shorter follow up duration was
also a limitation of the present study. TNFSF13 was only
associated with living related transplantation, and the
predictive value was not shown. Further studies in the
sufficient number of cohorts are needed to confirm
these findings and to show cut off values for the predict-
ive value of TNFSF13.
In summary, we identified an association between
pre-transplant serum TNFSF13 levels and IgAN recurrence
among patients who received a graft from a living related
donor. Our findings suggest that there may be a possible
role of TNFSF13 in IgAN recurrence among patients who
undergo living related donor graft transplantation.
Conclusions
This study provides evidence to suggest that pre-transplant
serum TNFSF13 levels is associated with recurrent IgAN
who had living related transplantation. Regarding the con-
cern of recurrence of IgAN on graft function, these results
require further studies to validate the role of TNFSF13 in
the recurrence of IgAN.
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